Truist downgraded Penumbra (PEN) to Hold from Buy with a price target of $374, up from $370. The firm cites the recent announcement of its acquisition by Boston Scientific for the downgrade. The deal is highly likely to close without issue, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEN: